• 407-549-3929
  • info@gapsos.com
Latest Peer Review Articles by our Clinical and Medical Team at Global Allied Pharmaceuticals

63.Frontline Treatment in Diffuse Large B-Cell Lymphoma(DLBCL) and the Futuristic Alternate Standard of Care for the First Line Therapy

Download Abstract Diffuse large B cell lymphoma (DLBCL) in the most common type of non-Hodgkin’s lymphoma (NHL) in developed world, so far and approximately 60,000 new non-Hodgkin lymphoma (NHL) cases and 20,000 deaths have been estimated in the United States […]

Read More

62.Competitive Treatment in Diffuse Large B-cell lymphoma (DLBCL) and the Future SOC for the First Line Therapy

Download Abstract Competitive Treatment in Diffuse Large B-cell lymphoma (DLBCL) and the Future SOC for the First Line Therapy Diffuse large B-cell lymphoma (DLBCL) in the most common type of non-Hodgkin’s lymphoma (NHL) in developed world, so far and approximately […]

Read More

61.Malignant melanoma

Abstract Download Worldwide incidence of malignant melanoma has been constantly increasing during the last years. Surgical excision is effective when primary tumors are thin with thickness of less than 1milli meter and there is no evidence of metastases. At later […]

Read More

60.Gastrointestinal Events Associated with Ipilimumab and combination therapies

Download Gastrointestinal Events Associated with Ipilimumab, Pazopanib, Anti PD1- Antibody and Their Management: Single and Combination Therapies Timothy Allen, MD, Ph.D1*, Giridhar M.N.V, MD,MBA1*, Ghazaleh Shoja E Razavi MD2 1Global Allied Pharmaceutical, Center for Excellence in Research & Development, USA. […]

Read More

59.PROTEASOME INHIBITION IN LYMPHOPROLIFERATIVE DISORDER.

Abstract Download Proteasomes are multi-subunit protein complexes, which present numerous targets for therapeutic interference. The most commonly used proteasome is 26S proteasome, which contains one 20S proteolytic core subunit and two 19S regulatory cap subunits. There are three different types […]

Read More

58. Toxicities Associated with Antibody Drug Conjugates

Abstract Download Conventional chemotherapeutic agents, in the treatment of several cancers, lack specificity, resulting in toxicities to normal tissues and poor therapeutic index. Antibody-based immunoconjugates are specifically targeted monoclonal antibodies that deliver the cytotoxic agent to the target cell. When […]

Read More

57.Mechanisms of drug resistance in Glioblastoma Multiforme.

Abstract Download Glioblastoma multiforme (GBM) is a group of low-grade as well as high-grade brain tumors that originate from the glia;neuroglial cells and are the most common and crucial brain tumor, specially in adults. The main causes are deemed to […]

Read More

56. A Review on Clinicopathological Correlation between Classical Inflammatory Bowel Disease and Immunotherapy Related Inflammatory Bowel Disease.

Abstract Download Blockade of various immune targets such as cytotoxic T-lymphocyte antigen-4 and Programmed cell death leads to immune-mediated tumor regression and immune-related adverse events, predominantly gastrointestinal events including diarrhea and colitis. The current review is done to understand the […]

Read More

55. A review of newer technologies in development of nanomedicines for cancers.

Abstract Download Cancer is the leading cause of morbidity and mortality worldwide. Advances in nanotechnology have contributed to the development of nanoparticles used for medical applications and optimized therapy. Due to unique features of nanoparticles, like a large surface area, […]

Read More

54. Safety and Efficacy of Peptide Based Vaccines.

Download Abstract A vaccine is a biological preparation which produces immunity from diseases or infections. A vaccine can be administeredby either of the route, orally (through mouth) or through needle injections or by aerosol [1]. Vaccine development process involves induction […]

Read More
Page 1 of 7
1 2 3 7
Stay in Touch with us by ...

Subscribe to our Newsletter